Lyn peptide inhibitor

Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH₂) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy^[1][2]. IC50 & Target:IC50: Lyn kinase^[1] In Vitro:Lyn peptide inhibitor (20 μM; 2 h) specifically blocks the binding of Lyn kinase to the βc subunit of IL-5/GM-CSF receptor in purified human eosinophils, without altering the binding of Jak2 to βc^[1].
Lyn peptide inhibitor (5-20 μM; 2 h) dose-dependently blocks IL-5-induced cellular protein tyrosine phosphorylation and Lyn kinase activation in purified human eosinophils, without inhibiting Jak2 kinase activation^[1].
N-stearoylated Lyn peptide inhibitor (20 μM; 2 h) blocks IL-5/IL-3-induced differentiation of mouse bone marrow cells into eosinophils. A significant inhibitory effect is observed on day 3 of culture, and this inhibitory effect persists until day 10 of culture^[1]
N-stearoylated Lyn peptide inhibitor (2-20 μM; 2 h) reduces IL-5-induced viability of purified human eosinophils in a dose-dependent manner, with significant decreases in cell viability observed at concentrations of 10 μM and 20 μM^[1]. In Vivo:The Lyn peptide inhibitor (2 mmol (≈0.5 mg); intrabronchial; single dose) significantly reduces allergen-induced airway eosinophil influx in a murine asthma model^[1].